CDISC Controlled Terminology across the Clinical Trial Continuum. Bay Area Implementation Network 6 March 2008
|
|
- Candace Knight
- 6 years ago
- Views:
Transcription
1 CDISC Controlled Terminology across the Clinical Trial Continuum Bay Area Implementation Network 6 March 2008 Bron Kisler Co-Founder / Director of Terminology
2 CDISC Terminology Initiative Overview / Background Terminology Development / Harmonization Production Spreadsheet TB & Cardiology Projects
3 Terminology Program Snapshot Formalized CDISC Terminology Program in 2005, initially focusing on SDTM terminology requirements Primary Objective: to develop and align terminology across all CDISC standards, spanning the clinical trial continuum (SDTM CDASH) Terminology Team comprised of 60+ team members (Global Pharmas, Regulators, Academia, CROs, etc.) with work distributed across 4 project teams Key partnership with US National Cancer Institute Enterprise Vocabulary Services (NCI EVS) Combined CDISC Terminology & HL7 RCRIM Vocabulary teams to ensure common development
4 Working Principles Evaluate and/or utilize existing terminology 1 st Expand existing vocabularies where incomplete, working with vocabulary developer / owner Harmonize across CDISC Models and with preexisting vocabulary initiatives Address international needs for global projects and organizations Ensure a sustainable open source environment and infrastructure for production terminology supporting terminology evolution
5 NCI EVS Partnership Dedicated terminology experts and resources CDISC controlled terminology development, harmonization, publication and maintenance CDISC work space in NCI Thesaurus with supporting infrastructure NCI EVS supports FDA vocabulary initiatives SPL, ICSR and RPS
6 Proposed Rule (key driver) Federal Register / Volume 71, No. 237 / Monday, December 11, 2006 The Food and Drug Administration is proposing to amend the regulations governing the format in which clinical study data and bioequivalence data are required to be submitted for new drug applications (NDAs), biological license applications (BLAs), and abbreviated new drug applications (ANDAs). The proposal would revise our regulations to require that data submitted for NDAs, BLAs, and ANDAs, and their supplements and amendments be provided in an electronic format that FDA can process, review, and archive. The proposal would also require the use of standardized data structure, terminology, and code sets contained in current FDA guidance (the Study Data Tabulation Model (SDTM) developed by the Clinical Data Interchange Standards Consortium) to allow for more efficient and comprehensive data review.
7 SDTM Domains Interventions Findings Events Exposure Labs InclExcl AE Adverse Events ConMeds Vitals SubjChar Disp. Subst Use PhysExam ECG MedHist QS **50+ SDTM fields identified as candidates for controlled terminology codelists
8 AE Relatedness field - AEREL AE Relatedness to Study Drug? (No standard Codelist defined) Company 1 No Unlikely Possible Probably Definite Company 2 Not Related Doubtful Possible Probable Very Likely Company 3 NO YES / Unknown
9 AE Relatedness field - AEREL AE Relatedness to Study Drug? (Standard Terminology Codelist aka Value Set ) CDISC Controlled Terminology Standard Codelist No Unlikely Possible Probably Definite
10 AE Relatedness field - AEREL AE Relatedness to Study Drug? (Standard Terminology across CDISC Standards) CDASH No Unlikely Possible Probably Definite SDTM No Unlikely Possible Probably Definite SEND No Unlikely Possible Probably Definite
11 Terminology Development & Harmonization
12 SDTM Terminology (production ~1600 terms) SDTM Package 1: 31 codelists & 825 controlled terms distributed broadly across SDTM Labtest Package 1: 2 codelists with 180 controlled terms for Analytes SDTM Package-2A: 7 code lists & 590 controlled terms for ECG, Con Meds, Drug Exposure and Substance Use, including Units & Frequency New Activities: assess production representation and usability; change requests & governance; maintenance & versioning (aligned with MedDRA)
13 SDTM Terminology (development ~650 terms) SDTM Package-2B: 12 code lists & 350 controlled terms developed and available for public review (AE, PE, VS and Subject Chars) Includes terminology set for anatomical location (SDTM LOC fields); both NCI Thesaurus and SNOMED were considered to be wellrepresentative of needs Labtest Package 2/3: SDTM: 200+ additional terms developed and available for public review (Labtest Package 2) SDTM/SEND: 100 terms in development for Vitamins, Enzymes, Immunology, Common drugs from drug screen (Labtest Package 3) Ongoing discussions with LOINC New SDTM projects to be launched in March per terminology gap analysis (SDTMIG 3.1.1, CDASH)
14 Internal Harmonization CDISC Glossary: to be represented in EVS NCI Thesaurus environment with SDTM terminology CDASH: aligning SDTM terminology with CDASH requirements; harmonization timeline pending SDTM-CDASH gap analysis SEND: initial gap analysis with SDTM complete; joint development activities underway BRIDG (HL7 RCRIM): high level analysis complete and harmonization plans in discussion
15 US Federal Harmonization NCI Thesaurus ICD s LOINC SNOMED MedDRA MeSH Controlled Vocabularies
16 External Harmonization (semantic links to healthcare) ISO: Global harmonization via ISO TC215 WG6 per proposal from ICH; participating standards organizations ISO, ICH, CEN, HL7 & CDISC LAB: discussing solution to link SDTM Labtest values with LOINC codes TB & Cardiology: CDISC and HL7 style artifacts released for public review Other: Imaging, Microbiology, PGx, Medical Devices
17 2008 Terminology Priorities 1. Finalize terminology needed for SDTM IG Ver Support / harmonize with other priority CDISC projects CDASH, SEND, Glossary, BRIDG 3. Support projects via HL7 RCRIM BRIDG, FDA Projects, CDISC-HL7 Message 4. Change control, governance and versioning 5. Develop integrated implementation plan to align terminology with other CDISC standards 6. New SDTM domains and semantic links with healthcare
18 Production Spreadsheet
19 Tuberculosis (TB) & Cardiology (CV) Projects
20 Sponsored by the US National Institutes of Health Primary Aim: Improve interoperability by standardizing CV & TB data elements NIH ROADMAP FOR MEDICAL RESEARCH RE-ENGINEERING THE CLINICAL RESEARCH ENTERPRISE ( CV & TB grants awarded to Duke University in 2005 )
21 Data Element: TB example Data Element Name: Reason subject first came to medical attention Clinical Definition: The reason the subject was first medically evaluated for possible TB disease or latent TB infection. Valid Values: (enumerated) Symptoms Contact investigation Source case investigation Screening of High Risk Population Other (Specify) Unknown
22 Key Objectives Develop and publish an initial set of CV & TB specific data standards clinical data elements, definitions and value sets Leveraging CDISC and HL7 standards processes, focus on methodology for developing therapeutic area data standards using case studies Produce useful products for CV & TB and report experience, process and best practices
23 Parallel Universes Patient Care World Clinical Research World TB: Diagnosis & Treatment of Pulmonary TB CDISC Healthcare Link CDISC Standard Terminology EHR (health record) CDASH (data collection) SDTM (submission) BRIDG Model
24 Results CDISC & HL7 Artifacts Use cases and storyboards (H) Data elements and clinical definitions (U) Domain Class model (H) Domain Activity diagram (H) Data collection forms (R) SDTM representation (R) H = Healthcare / R = Research / U = Universal
25 TB Data Standards Working Group Aeras Global TB Vaccine Foundation (Gates funded) Centers for Disease Control & Prevention (CDC) CDISC Duke University Med. Center FIND Diagnostics (Gates funded) Global TB Alliance (Gates funded) Health Level 7 National Cancer Institute National Heart, Lung & Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases (NIAID) National TB Control Assoc. Otsuka Tibotec (a J&J company) WHO Stop TB Partnership Other Global Pharmas
26 CDISC operates to advance the continued improvement of public health by enabling efficiencies in medical research and related areas of healthcare. Strength through collaboration As a catalyst for productive collaboration, CDISC brings together individuals spanning the healthcare continuum to develop global, open, consensus-based medical research data standards.
October, Integration and Implementation of CDISC Standards
Integration and Implementation of CDISC Standards October, 2008 Barbara Lentz, Associate Director, Electronic Data Management Standards, Processes & Training Pat Majcher, Statistical Reporting Services
More informationCDISC/TransCelerate Collaboration and TransCelerate work streams. -Clinical Data Standards -Common Protocol Template -esource
CDISC/TransCelerate Collaboration and TransCelerate work streams -Clinical Data Standards -Common Protocol Template -esource July 2016 TransCelerate Clinical Data Standards Project Opportunity
More informationCDASH Clinical Data Acquisition Standards Harmonization
CDISC Italian User Group Meeting 16 November 2007 CDASH Clinical Data Acquisition Standards Harmonization 1 Outline Background Organization Goals Timelinesand Process Review of progress Results Future
More informationLOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017
LOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017 Lauren Becnel, Ph.D. VP, Biomedical Informatics & Alliances, CDISC Asst Prof, Duncan Comprehensive Cancer Center,
More informationThe use of electronic Health Records in Clinical Research - The value of CDISC Standards
The use of electronic Health Records in Clinical Research - The value of CDISC Standards FH-Prof. Dr. Jozef Aerts University of Applied Sciences FH Joanneum Graz, Austria Who is Jozef Aerts? CDISC volunteer
More informationCDASH 2.0. Berlin Éanna Kiely CDISC Engineer
CDASH 2.0 Berlin Éanna Kiely CDISC Engineer 2016-09-13 Agenda CDASH 1.1 & CDASHIG 2.0 CDASH Concepts TAUG Examples Current Regulatory Perspective on CDASH Questions 2 CDASH: CDISC End to End Clinical Data
More informationClinical Data Acquisition Standards Harmonization (CDASH)
Clinical Data Acquisition Standards Harmonization () Prepared by: CDISC Team Section Table of Contents Page 1.0 Orientation... 1 1.1 Purpose... 1 1.2 Organization of this Document... 1 1.2.1 General Notes...2
More informationCDISC UK Network face to face Reading
CDISC UK Network face to face Reading Paul Houston, CDISC Head of European Operations CDISC Update and European Activity 2 CDISC Values and Principals Core value Foster CDISC community is altruistic
More informationPharmaSUG 2017 Paper DS14
PharmaSUG 2017 Paper DS14 Considerations in Submitting Standardized Electronic Data Under the Animal Rule: The Use of SDTMIG and SENDIG Domains, and the Need for New Domains and Concepts Fred Wood, Accenture
More informationSEMANTIC DATA PLATFORM FOR HEALTHCARE. Dr. Philipp Daumke
SEMANTIC DATA PLATFORM FOR HEALTHCARE Dr. Philipp Daumke ABOUT AVERBIS Founded: 2007 Location: Team: Focus: Current Sectors: Freiburg, Germany Domain & IT-Experts Leverage structured & unstructured information
More informationLab Results Interface (LRI) The Flexible Implementation Guide (IG) Standards and Interoperability Framework Initiative (ONC)
Lab Results Interface (LRI) The Flexible Implementation Guide (IG) Standards and Interoperability Framework Initiative (ONC) Ken McCaslin, FHL7 Director, Healthcare Standards Quest Diagnostics Co-chair
More informationImplementation and Operation of CDISC ODM-based EDC by UMIN
Implementation and Operation of CDISC ODM-based EDC by UMIN Takahiro Kiuchi, M.D., Ph.D. UMIN Center, The University of Tokyo Hospital, Tokyo, Japan 1 Content 1. CDISC standards and academic research 2.
More informationCDISC Data Standards Validation
CDISC Data Standards Validation How can it be done? Peter Van Reusel Business Unit Director Business & Decision Life Sciences Tel +32 2 774 11 00 Fax +32 2 774 11 99 Mobile +32 476 54 59 17 peter.vanreusel@businessdecision.com
More informationElectronic Health Records and Clinical Data Interchange Standards
Electronic Health Records and Clinical Data Interchange Standards Stephen E. Wilson, Dr.P.H., CAPT USPHS Director Division of Biostatistics III Center for Drug Evaluation and Research US Food and Drug
More informationVisualising CDISC SDTM for Monitoring and Review. Philip C. M. Bartle Clinical Innovation, PPD
Visualising CDISC SDTM for Monitoring and Review Philip C. M. Bartle Clinical Innovation, PPD Visualising CDISC SDTM for Monitoring and Review 1 2 3 4 5 6 7 Bringing CDISC SDTM Alive with Spotfire and
More informationE2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES
E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES PREPARING FOR E2B(R3) T he electronic transmission of adverse event information to stakeholders, using the International Conference on
More informationSonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration
FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for
More informationClinical Information Interoperability Council (CIIC) Providing a Shared Repository of Detailed Clinical Models for all of Health and Healthcare
Clinical Information Interoperability Council (CIIC) Providing a Shared Repository of Detailed Clinical Models for all of Health and Healthcare NIH HCS Collaboratory and PCORnet December 1, 2017 Stanley
More informationElectronic Healthcare Record and Clinical Research in Cardiovascular Radiology. HL7 CDA and CDISC ODM Interoperability
Electronic Healthcare Record and Clinical Research in Cardiovascular Radiology. HL7 CDA and CDISC ODM Interoperability A. El Fadly a, C. Daniel ab, C. Bousquet ab, T. Dart b, P-Y. Lastic c, P. Degoulet
More informationThe role of SNOMED CT in healthcare systems across the world Jan-Eric Slot MB MSc MBA CEO IHTSDO
The role of SNOMED CT in healthcare systems across the world Jan-Eric Slot MB MSc MBA CEO IHTSDO International Health Terminology Standards Development Organisation www.ihtsdo.org 1 Outline What is the
More informationPharmacovigilance and the Generic Industry. Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi
and the Generic Industry Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi Disclaimer: This presentation has been prepared by Biorasi, LLC solely for the purpose of sharing information and
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationPharmaSUG Paper PO12
PharmaSUG 2016 - Paper PO12 CDISC Standards End-to-End: Transitional Hurdles Alyssa Wittle, Chiltern International, King of Prussia, PA Christine McNichol, Chiltern International, King of Prussia, PA Antonio
More informationApplying SDTM and ADaM to the Construction of Datamarts in Support of Cross-indication Regulatory Requests
Applying SDTM and ADaM to the Construction of Datamarts in Support of Cross-indication Regulatory Requests Data-what? This presentation will discuss some of the complexities involved when integrating study
More informationExploration des données d essais cliniques en utilisant le standard CDISC
Exploration des données d essais cliniques en utilisant le standard CDISC Florence Kussener French System Engineer Florence.Kussener@jmp.com SAS Institute AGENDA Outcomes of using CDISC standards Case
More informationEvolving Regulatory Guidance on Submission of Standardized Data. James R. Johnson, PhD RTP CDISC User Network
Evolving Regulatory Guidance on Submission of Standardized Data James R. Johnson, PhD RTP CDISC User Network 2014-06-11 Originally Presented at PhUSE Conference 2013 Brussels, Belgium (Paper Number: RG03)
More informationGlobal Clinical Trials in Korea
Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials
More informationChapter 1. Pharmaceutical Industry Overview
Chapter 1 Pharmaceutical Industry Overview 1.1 Introduction 2 1.2 Regulations 2 1.2.1 Health Insurance Portability and Accountability Act 2 1.2.2 The Code of Federal Regulations 3 1.2.3 Guidance for Industry
More informationPCORI Methodology Standards: Academic Curriculum Patient-Centered Outcomes Research Institute. All Rights Reserved.
PCORI Methodology Standards: Academic Curriculum 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved. Module 5: Architecture for Data Networks Category 7: Data Networks as Research-Facilitating
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA
Post Marketing Safety Reporting (PMSR) Challenges and Successful Practices for Combination Products Objective Session Goals Summary of the final rule Interpretation for combination products approved as
More informationSpecific pathologist responses for Standard for Exchange of Nonclinical Data (SEND)
J Toxicol Pathol 2017; 30: 201 207 Review Specific pathologist responses for Standard for Exchange of Nonclinical Data (SEND) Atsushi Watanabe 1, 2*, Osamu Kusuoka 1, Norihiro Sato 1, Osamu Nakazono 1,
More informationDuane Steward, DVM, MSIE, PhD Nemours, Chief Computer Scientist for Clinical Informatics University Central Florida, Assistant Professor
Duane Steward, DVM, MSIE, PhD Nemours, Chief Computer Scientist for Clinical Informatics University Central Florida, Assistant Professor Agenda Define Health Information Exchange Key Issues Of Identification
More informationChristopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013
Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationWhat s New in HL7. W. Ed Hammond, PhD Director, Duke Center for Health Informatics FACMI, FAIMBE, FHL7, FIMIA Secretary, HL7; Chair-Emeritus, HL7
What s New in HL7 W. Ed Hammond, PhD Director, Duke Center for Health Informatics FACMI, FAIMBE, FHL7, FIMIA Secretary, HL7; Chair-Emeritus, HL7 In the beginning HL7 s initial venture into creating standards
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationRoadmap for Managing Multiple CRO Vendors
PharmaSUG 2017 - Paper PO27 Roadmap for Managing Multiple CRO Vendors Veena Nataraj, Shire, Lexington, MA Karin LaPann, Shire, Lexington, MA ABSTRACT When working with CROs, the relationship established
More informationCFAST Therapeutic Area Program Steering Committee 2013 Meeting Summaries (January-August)
CFAST Therapeutic Area Program Steering Committee 2013 Meeting Summaries (January-August) Participant full names and titles: Wayne: Wayne Kubick, Chief Technology Officer, CDISC (Chair) Becky: Rebecca
More informationIndustry Perspective of US Combination Product Rule: Postmarket Safety Reporting Challenges and Proposed Solutions
Industry Perspective of US Combination Product Rule: Postmarket Safety Reporting Challenges and Proposed Solutions June 2017 By: Khaudeja Bano, Chair of the Combination Products Coalition (CPC) Postmarket
More informationMaking the most of existing evidence in the OHDSI evidence generation environment
Making the most of existing evidence in the OHDSI evidence generation environment An update from the Knowledge Base (Laertes) workgroup Richard D Boyce, Martijn Schuemie, Anthony Sena April 12 th, 2016
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationInteroperability for clinical research Observational Health Data Sciences and Informatics (OHDSI)
9 ème École d'eté Méditerranéenne d'information en Santé Corte, France July 18, 2017 Interoperability for clinical research Observational Health Data Sciences and Informatics (OHDSI) Olivier Bodenreider
More informationPost-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER CSRC/DIA Think Tank June 3, 2016 Oanh Dang, PharmD, BCPS Division of Pharmacovigilance Safety Evaluator Office of Surveillance and
More informationThe Regulated Product Submission: Progress Update
The Regulated Product Submission: Progress Update IMDRF Public Stakeholders Session Sydney, Australia September 25-27, 2012 Mike Ward Chair, IMDRF RPS Working Group IMDRF RPS Proposal Composed of two complementary
More informationSNOMED CT in the Age of Precision Medicine
SNOMED CT in the Age of Precision Medicine Charles Gutteridge, Clinical Engagement Lead EMEA, SNOMED International @ gutteridgec HOW DO HUMANS ACT? 31414400 16064300 230063004 Dr Charles Gutteridge Clinical
More informationEmerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
More informationEHR4CR DEPLOYING INNOVATIVE CLINICAL TRIAL SERVICES. Brecht Claerhout, Custodix NV on behalf of the EHR4CR Consortium
EHR4CR DEPLOYING INNOVATIVE CLINICAL TRIAL SERVICES Brecht Claerhout, Custodix NV on behalf of the EHR4CR Consortium Electronic Health Records for Clinical Research Re-use of EHR data for optimizing Clinical
More informationEnd-to-End Management of Clinical Trials Data
End-to-End Management of Clinical Trials Data A Revolutionary Step Toward Supporting Clinical Trials Analysis Over the Next Decades of Clinical Research WHITE PAPER SAS White Paper Table of Contents Introduction....
More informationWestern Canada Chronic Disease Management Infostructure Initiative
Western Health Information Collaborative (WHIC) Western Canada Chronic Disease Management Infostructure Initiative CDM Data Standards Introduction FINAL - 08/10/2005 12:19 PM Prepared by Western Health
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More informationHL7 Plenary EHR In Canada
HL7 Plenary EHR In Canada September 11, 2006 Dennis Giokas Chief Technology Officer Canada Health Infoway, Inc Agenda Canada Health Infoway What is the EHR and It s Benefits Architecture and Standards
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationSpeed your time to market with FDA s expedited programs
Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In
More informationWebinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation.
Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation. Carolinas Collaborative Pilot RFA Webinar May 8, 2017 Partners Overview
More informationOptimizing Your Study Data Submissions to FDA Updates from CDER and CBER
This single PDF file contains the slides for all three presentations in the webinar: Optimizing Your Study Data Submissions to FDA Updates from CDER and CBER Please page down to find the slides for all
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More information9. Healthcare IT 안병익 U-HealthCare System
9. Healthcare IT 2011. 5. 25 안병익 (biahn99@gmail.com) Mcomputing.tistory.com @LBSAHN Outline HL7 CDA CDA for exchange networks CDA+CCR=CCD Summary, Resources & Questions 2 Health Level Seven (HL7.org) Standards
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationHealth Data Management
Western Technical College 10530176 Health Data Management Course Outcome Summary Course Information Description Career Cluster Instructional Level Total Credits 2.00 Total Hours 54.00 Introduces the use
More informationNCI Research Networks Model for Collaboration with Bioelectronics Round Table
NCI Research Networks Model for Collaboration with Bioelectronics Round Table Larry Clarke, Cancer Imaging Program DCDT, NCI Detail: NIBIB Guest Scientist: NIST 1 Bioelectronics Round Table Research Triangle
More informationFlorence Nightingale Notes on hospitals (1859, revised 1863)
In attempting to arrive at the truth, I have applied everywhere for information, but in scarcely an instance have I been able to obtain hospital records fit for any purposes of comparison. If they could
More informationIn This Issue September 9, 2010
In This Issue September 9, 2010 Message from the TSC Chair: Success and HL7 HL7 Tooling Report Promoting Attendance at the Sydney WGM: One Group s Strategy Updates from the TSC since the Last TSC Newsletter
More informationHITSP Construct HL7 Standard
EHR Lab Results Reporting HL7 /IS01 Clinical Document Architecture Release 2 (CDA R2) /C37 - Lab Report Document U.S. Realm - Interoperability Specification: Lab Result to EHR (ORU^R01) (HL7.1) September,
More information17/06/2014. GTA West DI r Project. Bringing Standardization into a non Standard World. Why is GTA West DI-r Necessary? What is the GTA West DI-r?
GTA West DI r Project Why is GTA West DI-r Necessary? Bringing Standardization into a non Standard World Mrs. S Lives in Northern Ontario Needs to go to PMH for a consultation What does her experience
More informationDrug Development Services
Drug Development Services Speaker Introduction Nik Burlew Vice President Regulatory and Strategic Development 25 Years in Pharma: Development, MFG and QA. Consulting for the last 13 years primarily to
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationMircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationEvolution of the CMC Review - ANDAs
Evolution of the CMC Review - ANDAs Susan Rosencrance, Ph.D. Director (Acting), Office of Lifecycle Drug Products Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research October 6,
More informationApril 13, Background
Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management
More informationIs FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D
Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite 1100 1050 Connecticut Ave., NW Washington, DC, 20036 D 202-861-1648 LShea@bakerlaw.com FMT Scenarios Intra-Office Bank Product The Issue The
More informationRelated Donor Informed Consent to Participate in Research
Related Donor Informed Consent to Participate in Research This is an informed consent document for a research study that your family member is participating in. This document will inform you about the
More informationCANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
More informationCDA vs Archetypes: Use Cases March Tomaž Gornik, Co-founder and CEO
CDA vs Archetypes: Use Cases March 2014 Tomaž Gornik, Co-founder and CEO $25M revenue Company facts 120 employed professionals 80 experienced software developers Products, References and domain knowledge
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationSNOMED CT to ICD-10 Project
SNOMED CT to ICD-0 Project Mapping Tool Feature Highlights, Demonstration and Adaptation for Other Mapping Work IHTSDO Implementation Showcase Sydney 3 October 20 20-0-20 Content Introduction and Background
More informationMEANINGFUL USE CRITERIA PHYSICIANS
MEANINGFUL USE CRITERIA PHYSICIANS The first list is of the 25 Stage 1 Meaningful Use criteria for eligible providers (EP) and comes from the proposed rule: "Medicare and Medicaid Programs; Electronic
More informationWHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific
WHITE PAPER establishing a regulatory Drug Development Strategy for Asia Pacific ppdi.com July 2012 EXECUTIVE SUMMARY As the economic power of China and other Asian countries grows, many biopharmaceutical
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationWelcome to the American College of Toxicology s Webinar Series. We will begin at 11AM EDT
Welcome to the American College of Toxicology s Webinar Series We will begin at 11AM EDT Preparing for Nonclinical edata Regulatory Submissions to the US FDA SEND and Beyond September 5, 2013, 11:00 AM
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationThe SDTMIG: What s New in 3.2
Accenture Life Sciences Rethink Reshape Restructure for better health outcomes. The SDTMIG: What s New in 3.2 Fred Wood Data Standards Consulting Lead Accenture Life Sciences RTP CDISC User Network March
More informationEU Regulation Review: challenges and opportunities for industry
EU Regulation Review: challenges and opportunities for industry Mia Bengtström, Pharma Industry Finland Nordic Pediatric Conference June 13,2017 Paediatric Regulation Consultation: EFPIA s answers general
More informationIndustry Experience: Early Collaboration with FDA on Combination Products. Kristi Kistner, Amgen Inc. CMC Strategy Form January 26, 2015
Industry Experience: Early Collaboration with FDA on Combination Products Kristi Kistner, Amgen Inc. CMC Strategy Form January 26, 2015 Collaboration is working together to achieve shared goals Given the
More informationRisk Based Approach To Complaint Handling
Risk Based Approach To Complaint Handling Khaudeja Bano, M.D. Senior Medical Director, Medical Device Safety Head, AbbVie Inc. Life Sciences Product Complaints Congress Europe Dublin, Ireland December
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationAepodia is a team of experts with more than 15 years
Aepodia is a team of experts with more than 15 years experience in early clinical development and translational science with small startup and large global pharmaceutical companies. Aepodia s team has
More informationataluren overview A New Approach to Genetic Disorders
ataluren overview A New Approach to Genetic Disorders Ataluren Scientific Background What is ataluren? Ataluren(formerly PTC124) is the first investigational therapy with the potential to enable the formation
More informationFDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond
FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond Jeff Shuren, MD, JD Center for Devices and Radiological Health U.S. Food and Drug Administration May 4, 2017 1
More informationHD Regulatory Science Consortium (HD-RSC) A consortium aimed at accelerating treatments for Huntington s disease
HD Regulatory Science Consortium (HD-RSC) A consortium aimed at accelerating treatments for Huntington s disease Critical Path Institute / CHDI Foundation Huntington s Disease Regulatory Science Consortium
More informationPharmaSUG PO14
PharmaSUG 2014 - PO14 Route to SDTM Implementation in In-Vitro Diagnostic Industry: Simple or Twisted Carey Smoak, Roche Molecular Systems, Inc., Pleasanton, CA Sofia Shamas, MaxisIT Inc., NJ Chowdagam
More informationUser Interface Considerations for Drug-Device Combination Products Submitted in an ANDA
User Interface Considerations for Drug-Device Combination Products Submitted in an ANDA Irene Z. Chan, PharmD, BCPS Deputy Director, Division of Medication Error Prevention and Analysis Disclaimer For
More information